Abstract
Rationale
Chronic treatment with the selective serotonin reuptake inhibitor, citalopram, normalizes several behavioral and neurochemical abnormalities in the olfactory bulbectomized (OBX) rat model of depression.
Objective
To assess the changes in regional cerebral glucose utilization (rCGU) following chronic treatment with citalopram in OBX and sham-operated rats.
Methods
Male Sprague Dawley rats (160–190 g) were used. Two weeks following the surgeries, the rats were implanted with osmotic minipumps which delivered 10 mg/kg/day of citalopram (the sham-CTP and OBX-CTP groups) or saline (to the sham-SAL and OBX-SAL groups) for 2 weeks. Following the treatment, the rates of rCGU were determined in 43 brain regions using 2-[14C]deoxyglucose (2-[14C]DG) autoradiography.
Results
The general linear model statistical analysis revealed significantly lower rCGU in the OBX-SAL group compared to the sham-SAL group in the medial prefrontal cortex and the median forebrain bundle. The sham-CTP group had significantly lower rCGU relative to the sham-SAL group in the medial prefrontal cortex. The OBX-CTP group had significantly lower rCGU than the OBX-SAL group in the anterior olfactory nucleus, orbitofrontal cortex, frontal cortex, anterior cingulate cortex, visual cortex, and substantia nigra—pars reticulata. The rCGU in the OBX-CTP group was significantly lower than that in the sham-CTP group in the anterior olfactory nucleus, orbitofrontal cortex, visual cortex, and substantia nigra—pars reticulata.
Conclusion
The results imply that chronic citalopram treatment, shown previously to result in behavioral normalization in OBX rats, establishes a new pattern of rCGU, rather than normalizing it to the pattern of the sham-CTP rats.
Similar content being viewed by others
Abbreviations
- 2-[14C]DG:
-
(2-[14C]deoxyglucose)5-HT (serotonin)
- ANOVA:
-
analysis of variance
- MANCOVA:
-
multivariate analysis of variance
- gCGU:
-
global cerebral glucose utilization
- rCGU:
-
regional cerebral glucose utilization
- DA:
-
dopamine
- MAO:
-
monoamino oxydase
- NA:
-
noradrenaline
- OBX:
-
olfactory bulbectomy
- OB:
-
olfactory bulbs
- OF:
-
open field
- PET:
-
positron emission tomography
- SERT:
-
serotonin transporter
- SSRI:
-
selective serotonin reuptake inhibitor
References
Auerbach SB, Hjorth S (1995) Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol 352:597–606
Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243–245
Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, Reynolds C (1997) Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 41:15–22
Caldecott-Hazard S, Mazziotta J, Phelps M (1988) Cerebral correlates of depressed behavior in rats, visualized using 14C-2-deoxyglucose autoradiography. J Neurosci 8(6):1951–1961
Cooper RM, Thurlow GA (1985) Depression and recovery of metabolic activity in rat visual system after eye removal. Exp Neurol 89(2):322–336
Duncan GE, Johnson KB, Breese GR (1993) Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci 13(9):3932–3943
Duncan GE, Knapp DJ, Johnson KB, Breese GR (1996) Functional classification of antidepressants based on antagonism of swim stress-induced fos-like immunoreactivity. J Pharmacol Exp Ther 277(2):1076–1089
Earley B, Glennon M, Lally M, Leonard BE, Junien JL (1994) Autoradiographic distribution of cholinergic muscarinic receptors and serotonin(2) receptors in olfactory bulbectomized (OB) rats after chronic treatment with mianserin and desipramine. Hum Psychopharmacol 9:397–407
Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA (1990) The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5(3):203–213
Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, Gilman S (2000) PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology 54(9):1768–1773
Freo U (1996) Cerebral metabolic effects of serotonin drugs and neurotoxins. Life Sci 59:877–891
Freo U, Ori C, Dam M, Merico A, Pizzolato G (2000) Effects of acute and chronic treatment with fluoxetine on regional glucose cerebral metabolism in rats: implications for clinical therapies. Brain Res 854:35–41
Freo U, Merico A, Ermani M, Ori C (2008) Cerebral metabolic effects of fluoxetine, fluvoxamine, paroxetine and sertraline in the conscious rat. Neurosci Lett. 436(2):148–152
Hasegawa S, Watanabe A, Nguyen KQ, Debonnel G, Diksic M (2005) Chronic administration of citalopram in olfactory bulbectomy rats restores brain 5-HT synthesis rates: an autoradiographic study. Psychopharmacology (Berl) 179:781–790
Holthoff VA, Beuthien-Baumann B, Zundorf G, Triemer A, Ludecke S, Winiecki P, Koch R, Fuchtner F, Herholz K (2004) Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand 110:184–194
Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1):19–26
Invernizzi R, Bramante M, Samanin R (1994) Chronic treatment with citalopram facilitates the effect of a challenge dose on cortical serotonin output: role of presynaptic 5-HT1A receptors. Eur J Pharmacol 260:243–246
Jueptner M, Weiller C (1995) Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 2:148–156
Kadekaro M, Crane AM, Sokoloff L (1985) Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci USA 82:6010–6013
Kelly JP, Wrynn AS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 74:299–316
Kennedy SH, Javanmard M, Vaccarino FJ (1997) A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Can J Psychiatry 42:467–475
Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS (2007) Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 164(5):778–788
Kuipers SD, Trentani A, Westenbroek C, Bramham CR, Korf J, Kema IP, Ter Horst GJ, Den Boer JA (2006) Unique patterns of FOS, phospho-CREB and BrdU immunoreactivity in the female rat brain following chronic stress and citalopram treatment. Neuropharmacology 50(4):428–440
Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME (1999) 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20:628–639
Lino-de-Oliveira C, Sales AJ, Del Bel EA, Silveira MC, Guimarães FS (2001) Effects of acute and chronic fluoxetine treatments on restraint stress-induced Fos expression. Brain Res Bull 55(6):747–754
Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P (2002) Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 159:1830–1840
Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, Lambas-Senas L, Wiborg O, Haddjeri N, Pineyro G, Sadikot AF, Debonnel G (2007) Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron 55:712–725
Marsteller DA, Barbarich-Marsteller NC, Patel VD, Dewey SL (2007) Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and gamma-amino butyric acid levels. Synapse 61:877–881
Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843
Moncrieff J, Cohen D (2005) Rethinking models of psychotropic drug action. Psychother Psychosom 74:145–153
Moncrieff J, Cohen D (2006) Do antidepressants cure or create abnormal brain states? PLoS Med 3:e240
Morgan JI, Curran T (1990) Inducible proto-oncogenes of the nervous system: their contribution to transcription factors and neuroplasticity. Prog Brain Res 86:287–294
Morilak DA, Frazer A (2004) Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 7:193–218
Nagano-Saito A, Kato T, Arahata Y, Washimi Y, Nakamura A, Abe Y, Yamada T, Iwai K, Hatano K, Kawasumi Y, Kachi T, Dagher A, Ito K (2004) Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage 22(2):553–561
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, Sydney
Roche M, Harkin A, Kelly JP (2007) Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate, and neuronal activation in the olfactory bulbectomized rat. Neuropsychopharmacology 32:1312–1320
Sato H, Skelin I, Debonnel G, Diksic M (2008) Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites. Brain Res Bull. 75(5):545–555
Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, Rafi-Tari S (2004) Limbic-frontal circuitry in major depression: a path modeling meta-analysis. Neuroimage 22(1):409–418
Skelin I, Sato H, Diksic M (2008) Olfactory bulbectomy reduces cerebral glucose utilization: 2-[14C]deoxyglucose autoradiographic study. Brain Res Bull 76:485–492
Smith GS, Reynolds CF 3rd, Pollock B, Derbyshire S, Nofzinger E, Dew MA, Houck PR, Milko D, Meltzer CC, Kupfer DJ (2001) Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry 156(5):683–689
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916
Stanic D, Finkelstein DI, Bourke DW, Drago J, Horne MK (2003) Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 18(5):1175–1188
van der Hart MG, Czéh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, Frahm J, Fuchs E (2002) Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry 7(9):933–941
van Riezen H, Leonard BE (1990) Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 47:21–34
Veening JG, Coolen LM, Spooren WJ, Joosten H, van Oorschot R, Mos J, Ronken E, Olivier B (1998) Patterns of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration. Eur Neuropsychopharmacol 8(3):213–226
Videbech P (2000) PET measurements of brain glucose metabolism and blood flow in major depressive disorder: a critical review. Acta Psychiatr Scand 101:11–20
Watanabe A, Hasegawa S, Nishi K, Nguyen KQ, Diksic M (2006) Chronic buspirone treatment normalizes regional serotonin synthesis in the olfactory bulbectomized rat brain: an autoradiographic study. Brain Res Bull 69(2):101–108
Zhou D, Grecksch G, Becker A, Frank C, Pilz J, Huether G (1998) Serotonergic hyperinnervation of the frontal cortex in an animal model of depression, the bulbectomized rat. J Neurosci Res 54:109–116
Acknowledgments
The research reported here was supported in part by grants from the Croatian Ministry of Science, Education, and Sports (219-1081970-2032) and Medical Research of Canada (MT-13368). The authors wish to thank Ms. Valerie Ann Cherneski for the editorial help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skelin, I., Sato, H., Kovačević, T. et al. Chronic therapy with citalopram decreases regional cerebral glucose utilization in OBX, and not sham-operated, rats: an autoradiographic study. Psychopharmacology 207, 315–323 (2009). https://doi.org/10.1007/s00213-009-1659-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-009-1659-4